Effektivnost' lozartana u bol'nykh arterial'noy gipertoniey s gipertrofiey miokarda levogo zheludochka


Cite item

Full Text

Abstract

References

  1. Hancock EW, Deal BJ, Mirvis DM, Okin P et al. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram: Part V: Electrocardiogram Changes Associated with Cardiac Chamber Hypertrophy A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society Endorsed by the International Society for Computerized Electrocardiology.J Am Coll Cardiol 2009; 53: 992-1002.
  2. Dahlöf B, Devereux RB, Kjeldsen SE et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
  3. Bender SR, Devereux RB, Okin PM. Risks of electrocardiography in hypertensive individuals and benefits of treatment-induced regression. Current Cardiovascular Risk Reports 2009; 3: 247-54.
  4. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2007: 25 (6): 1105-87.
  5. Okin PM, Gerdts E, Kjeldsen SE, Julius S et al. Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension study Investigators. Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertrnsive therapy. Hypertension 2008; 52 (1): 100-6. Epub 2008 May 26.
  6. Hsieh BP, Pham MX, Froelicher VF. Prognostic value of electrocardiographic criteria for left ventricular hypertrophy. Am heart J 2005; 150: 161-7.
  7. Barrios V, Escobar C, Calderon A et al. Prevalence of left ventricular hypertrophy detected by Cornell voltage-duration product in a hypertensive population. Blood Press 2008; 17 (2): 110.
  8. Okin PM, Devereux RB, Gerdts E et al. LIFE study Investigators. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during anthyipertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension study. Circulation 2006; 113 (12): 1588-96.
  9. Dahlöf B, Devereux RB, Julius S et al. for the LIFE Study Group. Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study. Hypertension 1998; 32: 989-97.
  10. Broun DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000; 140 (6): 848-56.
  11. Okin PM, Devereux RB, Jern S et al. for the LIFE Study Investigators. Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Treatment and the Prediction of Major Cardiovascular Events. JAMA 2004; 292: 2343-9.
  12. Чихладзе Н.М., Сивакова О.А., Самедова Х.Ф. и др. Сравнительный анализ антигипертензивной эффективности лозартана и эналаприла (исследование ЭЛЛА). Рац. фармакотер. в кардиол. 2008; 1: 44-8.
  13. Vakili BA, Okin PM, Devereux RB et al. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334-41.
  14. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). РМОАГ, ВНОК. М., 2010.
  15. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens 1991; 9 (Suppl.): S3-S8. Discussion S8-S9.
  16. Lonn E, Mathew J, Pogue J et al. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. Eu J cardiovasс Prev Rehabil 2003; 10: 420-8.
  17. Okin PM, Devereux RB, Nieminen MS et al. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension 2004; 44: 48-54.
  18. Чихладзе Н.М., Сахнова Т.А., Блинова Е.В. и др. Антигипертензивная и кардиопротективная эффективность лозартана у больных артериальной гипертензией с гипертрофией миокарда левого желудочка: результаты длительного (6-12 мес) наблюдения в условиях поликлинической практики. Системн. гипертенз. 2010; 4: 28-33.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 83918 от 12.09.2022 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 83917 от 12.09.2022 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies